Prevention of Skin Cancer by Scutellaria Baicalensis

黄芩预防皮肤癌

基本信息

  • 批准号:
    6632693
  • 负责人:
  • 金额:
    $ 26.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-09-18 至 2005-06-30
  • 项目状态:
    已结题

项目摘要

Chinese herbal medicine Huang Qin (Scutellaria baicalensis) has a variety of anti-inflammatory and anti-cancer activities. The central hypothesis of this proposal is that Scutellaria baicalensis extracts (SBE) inhibit ultraviolet (UV) B-induced pyrimidine dimers and oxidative DNA damage, and modulate UVB-activated signal transduction cascades and inflammatory responses, thereby suppressing the initiation and promotion of photocarcinogenesis. The initial aim of the project is to determine if pre- or post-application of SBE prevents UVB-induced skin carcinogenesis. The initial aim of the project is to determine if pre- or post-application of SBE prevents UVB-induced skin carcinogenesis. SBE will be topically applied to hairless mice during exposure to UVB. The protective effect will be evaluated by analyzing the latency period, tumor incidence and multiplicity. The second aim is to evaluated the effects of SBE on the initiation, promotion, and progression of photocarcinogenesis. A combined UVB-carcinogen model will be used to dissect the anti-initiational or anti-promotional effects of SBE on UBV- induced skin carcinogenesis. SBE will be topically applied to mouse skin before an initiating dose of UVB, followed by TPA promotion, or applied before UCB radiation in DMBA-initiated mice. The therapeutic effect of SBE will be tested on the existing cutaneous tumors by recording the tumor regression rate and malignant conversion rate. The third aim is to determine if SBE modifies UVB-induced intermediate endpoints relevant to initiation and promotion, e.g. DNA photoproducts, oxidative DNA damage, inflammatory responses, protooncogene expression and activation of AP-1 factor in vivo and in vitro. Lastly, we will further evaluate the efficacy of SBE in protection of UVB-induced erythema and discomfort in human skin. The molecular markers of DNA damage (pyrimidine dimers and 8-OHdG), apoptosis (p53 protein expression), and cell proliferation (PCNA) will be determined in the human skin biopsies as well as in 3-dimensional reconstituted human skin chronically exposed to UVB. Successful completion of the proposed studies will not only contribute to innovative use of herbal extracts as preventive and/or therapeutic agents against human skin cancer, but also promote the research on the anti-cancer action of BE in other human malignancies.
中草药黄芩具有多种抗炎、抗癌活性。该建议的中心假设是,黄芩提取物(SBE)抑制紫外线(UV)B诱导的嘧啶二聚体和氧化DNA损伤,并调节UVB激活的信号转导级联和炎症反应,从而抑制光致癌的启动和促进。该项目的最初目的是确定SBE应用前或应用后是否能防止UVB诱导的皮肤致癌作用。该项目的最初目的是确定SBE应用前或应用后是否能防止UVB诱导的皮肤致癌作用。在暴露于UVB期间,将SBE局部应用于无毛小鼠。将通过分析潜伏期、肿瘤发生率和多重性来评价保护作用。第二个目的是评估SBE对光致癌作用的启动、促进和进展的影响。将使用UVB-致癌物组合模型来剖析SBE对UBV诱导的皮肤致癌作用的抗引发或抗促进作用。在开始剂量的UVB之前,将SBE局部应用于小鼠皮肤,然后进行TPA促进,或者在DMBA启动的小鼠中在UCB辐射之前应用。将通过记录肿瘤消退率和恶变率来测试SBE对现有皮肤肿瘤的治疗效果。第三个目的是确定SBE是否改变UVB诱导的与启动和促进相关的中间终点,例如DNA光产物、氧化DNA损伤、炎症反应、原癌基因表达和AP-1因子在体内和体外的活化。最后,我们将进一步评估SBE在保护UVB引起的人体皮肤红斑和不适方面的功效。DNA损伤(嘧啶二聚体和8-OHdG)、细胞凋亡(p53蛋白表达)和细胞增殖(PCNA)的分子标志物将在人皮肤活检以及长期暴露于UVB的三维重建人皮肤中测定。这些研究的成功完成不仅将有助于创新地使用草药提取物作为预防和/或治疗人类皮肤癌的药物,而且还将促进BE在其他人类恶性肿瘤中抗癌作用的研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HUACHEN WEI其他文献

HUACHEN WEI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HUACHEN WEI', 18)}}的其他基金

GENISTEIN IN INVESTIGATIVE AND CLINICAL DERMATOLOGY
金雀花素在皮肤病学研究和临床中的应用
  • 批准号:
    6261199
  • 财政年份:
    2001
  • 资助金额:
    $ 26.99万
  • 项目类别:
GENISTEIN IN INVESTIGATIVE AND CLINICAL DERMATOLOGY
金雀花素在皮肤病学研究和临床中的应用
  • 批准号:
    6497975
  • 财政年份:
    2001
  • 资助金额:
    $ 26.99万
  • 项目类别:
GENISTEIN IN INVESTIGATIVE AND CLINICAL DERMATOLOGY
金雀花素在皮肤病学研究和临床中的应用
  • 批准号:
    6785642
  • 财政年份:
    2001
  • 资助金额:
    $ 26.99万
  • 项目类别:
GENISTEIN IN INVESTIGATIVE AND CLINICAL DERMATOLOGY
金雀花素在皮肤病学研究和临床中的应用
  • 批准号:
    6703674
  • 财政年份:
    2001
  • 资助金额:
    $ 26.99万
  • 项目类别:
GENISTEIN IN INVESTIGATIVE AND CLINICAL DERMATOLOGY
金雀花素在皮肤病学研究和临床中的应用
  • 批准号:
    6945538
  • 财政年份:
    2001
  • 资助金额:
    $ 26.99万
  • 项目类别:
GENISTEIN IN INVESTIGATIVE AND CLINICAL DERMATOLOGY
金雀花素在皮肤病学研究和临床中的应用
  • 批准号:
    6881484
  • 财政年份:
    2001
  • 资助金额:
    $ 26.99万
  • 项目类别:
GENISTEIN IN INVESTIGATIVE AND CLINICAL DERMATOLOGY
金雀花素在皮肤病学研究和临床中的应用
  • 批准号:
    6628448
  • 财政年份:
    2001
  • 资助金额:
    $ 26.99万
  • 项目类别:
SYNERGISTIC CARCINOGENICTY OF UVA AND BENZO(A)PYRENE
UVA 和苯并(A)芘的协同致癌作用
  • 批准号:
    6635489
  • 财政年份:
    2000
  • 资助金额:
    $ 26.99万
  • 项目类别:
Prevention of Skin Cancer by Scutellaria Baicalensis
黄芩预防皮肤癌
  • 批准号:
    6766005
  • 财政年份:
    2000
  • 资助金额:
    $ 26.99万
  • 项目类别:
Prevention of Skin Cancer by Scutellaria Baicalensis
黄芩预防皮肤癌
  • 批准号:
    6375454
  • 财政年份:
    2000
  • 资助金额:
    $ 26.99万
  • 项目类别:

相似海外基金

Complementary and alternative medicine for drug-induced gingival overgrowth: inhibitory effect of TRPA1 channel by lutein
药物性牙龈增生的补充和替代医学:叶黄素对 TRPA1 通道的抑制作用
  • 批准号:
    23K09321
  • 财政年份:
    2023
  • 资助金额:
    $ 26.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Complementary alternative medicine contributes to attenuate orofacial pain: anesthetic and anti-inflammatory effects of phytochemical
补充替代医学有助于减轻口面部疼痛:植物化学物质的麻醉和抗炎作用
  • 批准号:
    22K10232
  • 财政年份:
    2022
  • 资助金额:
    $ 26.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Negotiating distinctions between conventional and alternative medicine in the English- and French-language Wikipedias
英语和法语维基百科中讨论传统医学和替代医学之间的区别
  • 批准号:
    AH/V013203/1
  • 财政年份:
    2021
  • 资助金额:
    $ 26.99万
  • 项目类别:
    Research Grant
Systematic study on legal regulations for complementary and alternative medicine
补充替代医学法律法规的系统研究
  • 批准号:
    19K21680
  • 财政年份:
    2019
  • 资助金额:
    $ 26.99万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Contribution of complementary alternative medicine to the orthodontic tooth-movement induced inflammatory pain: a possible role of dietary constituent
补充替代医学对正畸牙齿移动引起的炎症性疼痛的贡献:饮食成分的可能作用
  • 批准号:
    19K10415
  • 财政年份:
    2019
  • 资助金额:
    $ 26.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Application of complementary and alternative medicine for breast cancer based on kinetic characteristics of food components
基于食物成分动力学特征的乳腺癌补充替代医学应用
  • 批准号:
    18K14416
  • 财政年份:
    2018
  • 资助金额:
    $ 26.99万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the Mechanism of Care Effectiveness Using Complementary and Alternative Medicine Material Detergent for Radiation Skin Damage
阐明补充和替代药物材料清洁剂对放射性皮肤损伤的护理效果机制
  • 批准号:
    18K17460
  • 财政年份:
    2018
  • 资助金额:
    $ 26.99万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Quality of clinical research papers on complementary and alternative medicine: evaluation with modified systematic reviews
补充和替代医学临床研究论文的质量:用修改后的系统评价进行评估
  • 批准号:
    17K08938
  • 财政年份:
    2017
  • 资助金额:
    $ 26.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Formulation for the Application of the Energy Therapy "Reiki" as Complementary and Alternative Medicine for Cancer Patient
应用能量疗法“灵气”作为癌症患者的补充和替代医学的配方
  • 批准号:
    16K15906
  • 财政年份:
    2016
  • 资助金额:
    $ 26.99万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Boundaries between Orthodox Medicine and Alternative Medicine
正统医学与替代医学之间的界限
  • 批准号:
    16K21422
  • 财政年份:
    2016
  • 资助金额:
    $ 26.99万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了